We conduct first-in-the-world, state-of-the art clinical research in a range of neurological conditions. Our goal is to safely, but rapidly, change the clinical landscape by implementing innovative clinical diagnostics and treatments to those impacted by neurological disease. We are initially focused on Alzheimer’s, addiction, and chronic pain. However, our goal is to improve the functional outcomes of those with a full range neurological conditions. We are fortunate to have federal and industry partners, who share our mission and vision and support this transformative work. We work closely with our university colleagues, such as the West Virginia Center for Clinical & Translational Science (WV CTSI), to maximize our efficiency and outcomes. Below are a few examples of our barrier breaking clinical trials:
Focused ultrasound for blood brain barrier opening in Alzheimer’s disease
In collaboration with INSIGHTEC, we have successfully opened the blood brain barrier in the hippocampus of patients with mild Alzheimer’s disease.
Non-opioid micropellet implantation for chronic pain
In collaboration with Sollis, we have successfully implanted a micropellet that contains no opioids to treat a form a chronic back pain.
Deep brain stimulation for Opioid Use Disorder
Funded by the National Institute of Drug Abuse and in collaboration with Medtronic, we are using deep brain stimulation for those individuals at high risk of death who have failed standard treatments for opioid use disorder.
Transcranial magnetic stimulation for the treatment of addiction
In collaboration with Magstim, we are using transcranial magnetic stimulation to improve the outcomes of those who have failed standard treatment for addiction.
Transcranial magnetic stimulation and virtual reality in Alzheimer’s disease
Funded by the National Institute of Aging and the WV CTSI and in collaboration with MindMaze and Magstim, we are examining the efficacy of trancranial magnetic stimulation in combination with virtual reality to slow the progression of Alzheimer’s disease.
Using wearable technology to monitor outcome in Opioid use Disorder
Funded by the National Institute of General Medical Sciences and the WV CTSI, we are studying the use of wearable technology to monitor physiological, cognitive, and behavioral biomarkers to model the outcomes in patients with addiction.
Dr. Ali Rezi, executive chair of the West Virginia University Rockefeller Neuroscience Institute, lays out his bold, new vision for the neurosciences at WVU. Joining Dr. Rezai are WVU President Gorden Gee, Albert Wright, president and chief executive officer of the West Virginia University Health System, and Clay Marsh, MD, vice president and executive dean for Health Science at WVU.
Research drives patient care at any large academic medical center. As stroke treatment has dramatically evolved in the past decade, WVU Medicine’s neurointerventionists have emerged as national leaders in their relatively new field. Here, Ansaar Rai, M.D., WVU Medicine Radiology vice chair of clinical operations, discusses the past and present of stroke treatment.
Neurosurgeons treat their patients through the use of a delicate, targeted procedure; the best neurosurgeons are skilled at several. WVU Medicine neurosurgeon Robert A. Marsh, MD, PhD, says his best approach is unique to each patient, and considers wishes as well as needs.